Free Trial

William Blair Issues Negative Outlook for InnovAge Earnings

InnovAge logo with Medical background

InnovAge Holding Corp. (NASDAQ:INNV - Free Report) - Equities research analysts at William Blair dropped their Q2 2025 earnings estimates for InnovAge in a report issued on Tuesday, November 5th. William Blair analyst J. Haase now anticipates that the company will post earnings of $0.00 per share for the quarter, down from their previous estimate of $0.01. The consensus estimate for InnovAge's current full-year earnings is ($0.02) per share. William Blair also issued estimates for InnovAge's Q4 2025 earnings at $0.00 EPS and FY2026 earnings at $0.06 EPS.

InnovAge (NASDAQ:INNV - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.04) EPS for the quarter, meeting analysts' consensus estimates of ($0.04). The business had revenue of $205.14 million during the quarter, compared to analyst estimates of $203.35 million. InnovAge had a negative return on equity of 7.43% and a negative net margin of 2.79%. During the same period in the previous year, the company posted ($0.08) EPS.

Separately, KeyCorp initiated coverage on shares of InnovAge in a research report on Friday, October 11th. They issued a "sector weight" rating for the company.

View Our Latest Report on INNV

InnovAge Stock Down 3.8 %

Shares of NASDAQ INNV traded down $0.24 during midday trading on Thursday, hitting $6.06. 47,947 shares of the stock traded hands, compared to its average volume of 37,184. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.25 and a current ratio of 1.25. InnovAge has a one year low of $3.52 and a one year high of $6.69. The business has a 50 day moving average price of $5.92 and a two-hundred day moving average price of $5.37. The company has a market cap of $821.13 million, a PE ratio of -37.88 and a beta of 0.39.

Insider Activity at InnovAge

In other InnovAge news, insider Nicole Damato sold 4,372 shares of the business's stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $5.95, for a total transaction of $26,013.40. Following the completion of the sale, the insider now directly owns 240,795 shares of the company's stock, valued at approximately $1,432,730.25. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.40% of the stock is owned by insiders.

Hedge Funds Weigh In On InnovAge

Hedge funds have recently bought and sold shares of the company. Rhumbline Advisers lifted its position in shares of InnovAge by 7.0% during the second quarter. Rhumbline Advisers now owns 27,503 shares of the company's stock valued at $136,000 after purchasing an additional 1,793 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of InnovAge by 3.1% during the 2nd quarter. Renaissance Technologies LLC now owns 136,400 shares of the company's stock worth $677,000 after buying an additional 4,100 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of InnovAge by 27.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,322 shares of the company's stock worth $289,000 after buying an additional 12,448 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of InnovAge by 0.7% in the first quarter. Vanguard Group Inc. now owns 1,842,764 shares of the company's stock valued at $8,182,000 after acquiring an additional 13,193 shares in the last quarter. Finally, Kent Lake Capital LLC increased its position in shares of InnovAge by 3.7% during the first quarter. Kent Lake Capital LLC now owns 1,750,000 shares of the company's stock valued at $7,770,000 after acquiring an additional 62,141 shares during the last quarter. 12.26% of the stock is owned by hedge funds and other institutional investors.

InnovAge Company Profile

(Get Free Report)

InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management.

Featured Articles

Earnings History and Estimates for InnovAge (NASDAQ:INNV)

Should you invest $1,000 in InnovAge right now?

Before you consider InnovAge, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InnovAge wasn't on the list.

While InnovAge currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Why Whitestone REIT is Outperforming in 2024: 35% Growth & Monthly Dividends
Why SoundHound Stock Dip Could Mean Big Gains for 2025 Investors
Nintendo Stock: Buy Before the 2025 Switch Platform Hits!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines